Vanguard Capital Management filed a Schedule 13G with the SEC on October 30, 2026, disclosing beneficial ownership of 5,725,578 shares of Immunome Inc common stock, representing 5.04% of the class, based on a triggering event dated September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Capital Management reported beneficial ownership of 5,725,578 shares of Immunome Inc common stock.
  • Percent of class: The reported stake represents 5.04% of the outstanding common stock.
  • Sole voting power: Vanguard Capital Management holds sole power to vote 843,447 shares, with shared voting power of 0.
  • Sole dispositive power: Sole power to dispose of all 5,725,578 shares is reported, with shared dispositive power of 0.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Filing entity type: Vanguard Capital Management is classified as an investment adviser (type "IA") and is organized in Pennsylvania.

Vanguard Capital Management Crosses 5% Ownership Threshold in Immunome Inc Common Stock

According to the Schedule 13G filing, Vanguard Capital Management, headquartered at 100 Vanguard Blvd, Malvern, PA 19355, disclosed that it beneficially owns 5,725,578 shares of common stock of Immunome Inc (NASDAQ:IMNM), whose principal executive offices are located at 18702 North Creek Parkway, Suite 100, Bothell, WA 98011. The filing was submitted on October 30, 2026, with a triggering event date of September 30, 2026. The CUSIP number for the reported securities is 45257U108.

The filing notes, in accordance with SEC Release No. 34-39538 (January 12, 1998), that the Schedule 13G reflects securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and certain named affiliates and business divisions, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd. The filing states that it includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, as well as securities held by clients over which the listed affiliates or business divisions exercise dispositive and/or voting power.

The filing further discloses that Vanguard Capital Management, "including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein," and that no single other person's interest in the reported securities exceeds 5%. The statement was signed by My Trieu-Gatt, identified as Authorized Signatory, Head of Global Fund Administration, on October 30, 2026.

What Was Disclosed

Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 5,725,578 shares of Immunome Inc common stock, equaling 5.04% of the class, with sole dispositive power over all reported shares and sole voting power over 843,447 shares.